These authors also carried out the structural modeling of the catalytic domain of ADAM15, and subsequently designed a specific sulfonamide inhibitor of this metalloproteinase that in vitro reduced significantly the viability of bladder cancer cells and was also effective in human bladder cancer xenografts. The gene discussed is ADAM15; the disease is urinary bladder carcinoma.